Base de dados : MEDLINE
Pesquisa : E02.120.142 [Categoria DeCS]
Referências encontradas : 1097 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 110 ir para página                         

  1 / 1097 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26782476
[Au] Autor:Wei XC; Yang DD; Han XR; Zhao YA; Li YC; Zhang LJ; Wang JJ
[Ad] Endereço:Institute of hematological research, Shaanxi Provincial People's Hospital, Xi'an, China.
[Ti] Título:Effects of CD3McAb and rhIL-2 activated bone marrow on the killing and purging of leukemia cells.
[So] Source:Genet Mol Res;14(4):18287-92, 2015 Dec 28.
[Is] ISSN:1676-5680
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:We investigated the roles of CD3McAb and rhIL-2 activated bone marrow in the killing and purging of leukemia cells. Cytotoxicity of activated bone marrow was detected with MTT assay. CFU-GM level in activated bone marrow and the destruction of leukemia cells were measured using the semi-solid cell culture. Immune activation markers in activated bone marrow were detected by indirect immunofluorescence assay. Bone marrow activated by CD3McAb and rhIL-2 displayed significantly upregulated the killing and purging abilities on the leukemia cell line K562 and HL-60. Such effects were superior to that of bone marrow activated by rhIL-2 or CD3McAb alone (P < 0.05, P < 0.01). Activation by rhIL-2 and (or) CD3McAb exerted no obvious influence on CFU-GM level in bone marrow. Compared with bone marrow activated by rhIL-2 or CD3McAb alone, the synergistic effect of both CD3McAb+ and hIL-2 caused significant increase of CD3(+), CD8(+), CD19(+), CD25(+), CD38(+), and CD56(+) levels. Our study indicates that CD3McAb enhanced the killing and purging effects of rhIL-2 activated bone marrow on leukemia cells.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/farmacologia
Células da Medula Óssea/efeitos dos fármacos
Purging da Medula Óssea
Interleucina-2/farmacologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Anticorpos Monoclonais/imunologia
Células da Medula Óssea/metabolismo
Células da Medula Óssea/patologia
Purging da Medula Óssea/métodos
Transplante de Medula Óssea
Complexo CD3/imunologia
Complexo CD3/metabolismo
Linhagem Celular Tumoral
Sobrevivência Celular/efeitos dos fármacos
Ensaio de Unidades Formadoras de Colônias
Feminino
Células Progenitoras de Granulócitos e Macrófagos
Células HL-60
Seres Humanos
Imunofenotipagem
Células K562
Leucemia/metabolismo
Leucemia/patologia
Leucemia/terapia
Masculino
Meia-Idade
Fenótipo
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (CD3 Complex); 0 (Interleukin-2)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160120
[St] Status:MEDLINE
[do] DOI:10.4238/2015.December.23.16


  2 / 1097 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:25702654
[Au] Autor:Escobar IG; Sánchez de Ibarguen BC; de Juan VC; Alonso CM; García MM; Ruíz AC; Pulla MP
[Ti] Título:High-dose chemotherapy followed by autologous and allogeneic hematopoietic stem cell transplantation in patients with follicular non-Hodgkin's lymphoma in the rituximab era.
[So] Source:Tumori;101(1):2-7, 2015 Jan-Feb.
[Is] ISSN:2038-2529
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:High-dose chemotherapy in lymphomas, and mainly non-Hodgkin's lymphomas, has been advancing since the 1970s. This therapeutic strategy is based on the supposed existence of a dose-response curve for cytotoxic agents. However, the available data are contradictory, so high-dose chemotherapy cannot be guaranteed as consolidation treatment for first-remission follicular lymphoma or diffuse large cell lymphoma. The objective of this paper is to review the current knowledge about high-dose chemotherapy followed by hematopoietic stem cell transplantation in follicular non-Hodgkin's lymphoma. The published studies on follicular lymphoma after first remission, recurrent follicular lymphoma, and transformed follicular ­lymphoma were assessed together with the data available on diffuse large cell lymphoma. During analysis of the studies, difficulties were encountered in comparing studies due to the heterogeneous nature of the data. High-dose chemotherapy as consolidation treatment after first remission or in recurrent or refractory disease was also analyzed.
[Mh] Termos MeSH primário: Anticorpos Monoclonais Murinos/uso terapêutico
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Transplante de Células-Tronco Hematopoéticas
Fatores Imunológicos/uso terapêutico
Linfoma Folicular/terapia
Terapia Neoadjuvante/métodos
[Mh] Termos MeSH secundário: Purging da Medula Óssea
Ensaios Clínicos como Assunto
Esquema de Medicação
Medicina Baseada em Evidências
Seres Humanos
Linfoma Folicular/tratamento farmacológico
Linfoma Folicular/cirurgia
Recidiva
Rituximab
Transplante Autólogo
Transplante Homólogo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Murine-Derived); 0 (Immunologic Factors); 4F4X42SYQ6 (Rituximab)
[Em] Mês de entrada:1506
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150224
[St] Status:MEDLINE


  3 / 1097 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25627833
[Au] Autor:Burton AG; Clark KC; Borjesson DL; Carrade DD; Burges J; Owens SD
[Ad] Endereço:Veterinary Medical Teaching Hospital, University of California-Davis, Davis, CA, USA.
[Ti] Título:Equine bone marrow volume reduction, red blood cell depletion, and mononuclear cell recovery using the PrepaCyte-CB processing system.
[So] Source:Vet Clin Pathol;44(2):188-93, 2015 Jun.
[Is] ISSN:1939-165X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Volume reduction and RBC depletion of equine bone marrow specimens are necessary processing steps for the immediate therapeutic use of bone marrow (BM)-derived mesenchymal stem cells (MSC), and for MSC expansion in culture. OBJECTIVES: The purpose of the study was to evaluate the ability of the PrepaCyte-CB processing system to reduce volume, deplete RBC, and recover mononuclear cells (MNC) from equine BM specimens. METHODS: One hundred and twenty mL of heparinized BM were obtained from each of 90 horses. A CBC was performed on the BM pre- and post-PrepaCyte-CB processing. Volume and RBC reduction, and total nucleated cell (TNC) and MNC recoveries were determined. RESULTS: Bone marrow volume was reduced from 120 mL to 21 mL with a median RBC depletion of 90.1% (range, 62.0-96.7%). The median preprocessing total TNC count was 2.2 × 10(9) (range, 0.46-7.9 × 10(9)) and the median postprocessing TNC count was 1.7 × 10(9) (range, 0.3-4.4 × 10(9); P < .0001), with a median recovery of 73.5% (range, 22.4-216.7%). The median preprocessing total MNC count was 0.9 × 10(9) (range, 0.1-4.7 × 10(9)) and median postprocessing total MNC count was 0.8 × 10(9) (range, 0.1-2.7 × 10(9); P = .06), with a median recovery of 83.7% (range, 15.4-413.9%). CONCLUSIONS: The PrepaCyte-CB processing system can be used to deplete both volume and RBC, and recover MNC from equine BM specimens. Further studies assessing the viability of MSC and the efficacy of MSC expansion after using the PrepaCyte-CB processing system are warranted.
[Mh] Termos MeSH primário: Purging da Medula Óssea/veterinária
Medula Óssea/química
Separação Celular/veterinária
Eritrócitos/citologia
Cavalos/fisiologia
Leucócitos Mononucleares/citologia
[Mh] Termos MeSH secundário: Animais
Purging da Medula Óssea/instrumentação
Separação Celular/instrumentação
Contagem de Eritrócitos/veterinária
Volume de Eritrócitos/veterinária
Eritrócitos/fisiologia
Leucócitos Mononucleares/fisiologia
Manejo de Espécimes
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1603
[Cu] Atualização por classe:161020
[Lr] Data última revisão:
161020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150129
[St] Status:MEDLINE
[do] DOI:10.1111/vcp.12236


  4 / 1097 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24595415
[Au] Autor:Marnitz S; Zich A; Martus P; Budach V; Jahn U; Neumann O; Arnold R
[Ad] Endereço:Department of Radiation Oncology, Charité University Medicine, Augustenburger Platz 1, 13353, Berlin, Germany, simone.marnitz@charite.de.
[Ti] Título:Long-term results of total body irradiation in adults with acute lymphoblastic leukemia.
[So] Source:Strahlenther Onkol;190(5):453-8, 2014 May.
[Is] ISSN:1439-099X
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The aim of this chart review of adult patients treated for acute lymphoblastic leukemia (ALL) with total body irradiation (TBI) was to evaluate early and late toxicity and long-term outcome. PATIENTS AND METHODS: A total of 110 adult patients (34 ± 12 years) with ALL underwent TBI (6 fractions of 2 Gy for a total of 12 Gy) as a part of the treatment regimen before transplantation. Treatment-related toxicity, mortality, and hematologic outcome are reported. RESULTS: Mean follow-up was 70 months. The 2- and 5-year leukemia-free survival rates were 78 and 72%, respectively. In all, 29% (32/110) patients suffered from medullary recurrence after a median time of 7 months. Gender was the only statistically significant prognostic factor in terms of overall survival in favor of female patients. Treatment-related mortality and overall survival after 2 and 5 years were 16 and 22%, and 60 and 52.7%, respectively. The most frequent late reaction wascGVHD of the skin (n = 33, 30%). In addition, 15.5% (17/110 patients) suffered pulmonary symptoms, and 6 patients developed lung fibrosis. Eyes were frequently affected by the radiation (31/110 = 28%); 12 of 110 patients (11%) presented with symptoms from osteoporosis, 5 of 110 patients (4.5%) developed hypothyreosis and 2 patients diabetes mellitus. Of the male patients, 11% reported erectile dysfunction or loss of libido, while 2 of 36 women reported menopausal syndrome at the mean time of 28 months after treatment with requirement for substitution. No women became pregnant after treatment. No acute or late cardiac toxicities were documented in our patients. No secondary malignancies were documented. CONCLUSION: Although hematologic outcome was in the upper range of that reported in the literature, treatment-related mortality (TRM) and medullary recurrences remain a challenge. Sophisticated radiation techniques allow for decreasing toxicity to certain organs and/or dose escalation to the bone marrow in highly selected patients in order to improve therapeutic breadth.
[Mh] Termos MeSH primário: Leucemia-Linfoma Linfoblástico de Células Precursoras/radioterapia
Irradiação Corporal Total
[Mh] Termos MeSH secundário: Adulto
Purging da Medula Óssea
Terapia Combinada
Intervalo Livre de Doença
Feminino
Doença Enxerto-Hospedeiro/etiologia
Transplante de Células-Tronco Hematopoéticas
Seres Humanos
Estudos Longitudinais
Masculino
Meia-Idade
Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidade
Lesões por Radiação/etiologia
Lesões por Radiação/mortalidade
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1406
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140306
[St] Status:MEDLINE
[do] DOI:10.1007/s00066-014-0607-3


  5 / 1097 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24266323
[Au] Autor:Yahng SA; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Kim DW; Lee JW; Min WS; Park CW; Kim Y; Cho SG
[Ad] Endereço:Department of Haematology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
[Ti] Título:Influence of ex vivo purging with CliniMACS CD34(+) selection on outcome after autologous stem cell transplantation in non-Hodgkin lymphoma.
[So] Source:Br J Haematol;164(4):555-64, 2014 Feb.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The major limitation of autologous stem cell transplantation (auto-SCT) in non-Hodgkin lymphoma (NHL) is relapse. Although autologous graft contamination may be a potential cause, prior purging of the autograft remains controversial. Therefore, we retrospectively analysed 56 consecutive patients with NHL receiving auto-SCT at complete (n = 41) or partial remission (n = 15). Among them, 24 patients underwent autograft manipulation with positive selection of CD34(+) cells using a CliniMACS device (purged group). Twenty-five patients had received ≥2 previous chemotherapy regimens before auto-SCT. After a median follow-up of 41·4 months, transplant-related mortality was observed only in unpurged group (n = 2; 3·6%). The 3-year overall survival (91·7% vs. 56·1%, P = 0·009) and progression-free survival (78·7% vs. 53·1%, P = 0·034) favoured CD34(+) purification. While neutrophil recovery was similar, platelet recovery was delayed in the purged group. Cytomegalovirus reactivation was predominantly observed in the purged group, although no other clinically unmanageable infectious complications occurred. Although this study has the inevitable limitations of heterogeneity in previous treatment and NHL subtypes, and a small number of patients analysed, the high survival rate in the purged group may suggest the need for prospective randomized trials to determine the role of CD34(+) purification in auto-SCT for NHL.
[Mh] Termos MeSH primário: Antígenos CD34/imunologia
Purging da Medula Óssea/métodos
Transplante de Células-Tronco Hematopoéticas/métodos
Linfoma não Hodgkin/cirurgia
Condicionamento Pré-Transplante/métodos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Antígenos CD34/metabolismo
Intervalo Livre de Doença
Feminino
Seres Humanos
Masculino
Meia-Idade
Estudos Retrospectivos
Transplante Homólogo
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antigens, CD34)
[Em] Mês de entrada:1406
[Cu] Atualização por classe:140127
[Lr] Data última revisão:
140127
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:131126
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.12664


  6 / 1097 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24042348
[Au] Autor:Caes L; Vervoort T; Devos P; Verlooy J; Benoit Y; Goubert L
[Ad] Endereço:*Centre for Pediatric Pain Research, IWK Health Centre, Halifax, Nova Scotia, Canada †Department of Experimental-Clinical and Health Psychology, Ghent University ‡Department of Pediatric Oncology/Hematology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium.
[Ti] Título:Parental distress and catastrophic thoughts about child pain: implications for parental protective behavior in the context of child leukemia-related medical procedures.
[So] Source:Clin J Pain;30(9):787-99, 2014 Sep.
[Is] ISSN:1536-5409
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Treatment for childhood leukemia requires frequent lumbar punctures (LP) and bone marrow aspirations (BMA), often described by children and parents as more distressing than the disease itself. Findings in schoolchildren and chronic pain samples indicate that increased parental distress may increase parental protective, pain-attending behavior, which is associated with more child pain and distress. However, in the context of invasive medical procedures, it is unknown which parents are likely to become most distressed and engage in pain-attending behavior, and how this impacts the children's experiences. The present study investigated the impact of parental catastrophic thoughts upon parental distress and pain-attending behavior (verbal and nonverbal). Furthermore, the association between parental responses and the children's pain behavior, pain, and distress was examined. MATERIALS AND METHODS: A total of 46 parents of children with leukemia (range, 0.6 to 15 y) who underwent a LP/BMA procedure participated in this study. Parental catastrophizing was assessed before and parental and child distress was assessed after the LP/BMA procedure. Parental pain-attending behavior and the child's pain behavior were observed before and after the LP/BMA procedure. RESULTS: Findings indicated that heightened parental catastrophic thinking contributed to increased parental distress during LP/BMA and less pain-attending behavior before the LP/BMA procedure, especially in young children. In contrast, heightened distress in parents with high levels of catastrophizing contributed to increased engagement in postprocedural pain-attending behavior. For young children, increased preprocedural pain-attending behavior was related to more child distress, pain, and pain behavior. DISCUSSION: The findings demonstrate the importance of parental catastrophic thinking in understanding their caregiving responses and preparing parents and children for painful invasive medical procedures.
[Mh] Termos MeSH primário: Catastrofização
Leucemia/fisiopatologia
Dor/fisiopatologia
Pais/psicologia
Estresse Psicológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Fatores Etários
Purging da Medula Óssea/efeitos adversos
Purging da Medula Óssea/psicologia
Criança
Pré-Escolar
Feminino
Seres Humanos
Lactente
Leucemia/psicologia
Leucemia/terapia
Masculino
Meia-Idade
Dor/etiologia
Dor/psicologia
Relações Pais-Filho
Punção Espinal/efeitos adversos
Punção Espinal/psicologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1507
[Cu] Atualização por classe:140806
[Lr] Data última revisão:
140806
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130918
[St] Status:MEDLINE
[do] DOI:10.1097/AJP.0000000000000028


  7 / 1097 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23974608
[Au] Autor:Thirukkumaran CM; Shi ZQ; Luider J; Kopciuk K; Bahlis N; Neri P; Pho M; Stewart D; Mansoor A; Morris DG
[Ad] Endereço:1] Department of Oncology, University of Calgary, Calgary, Alberta, Canada [2] Department of Oncology, Tom Baker Cancer Center, Calgary, Alberta, Canada.
[Ti] Título:Reovirus as a successful ex vivo purging modality for multiple myeloma.
[So] Source:Bone Marrow Transplant;49(1):80-6, 2014 Jan.
[Is] ISSN:1476-5365
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Autologous stem cell rescue (ASCT) following high-dose myeloablative chemotherapy is considered to be a therapeutic option for many multiple myeloma (MM) patients; however relapse post ASCT presents a major challenge. The oncolytic potential of reovirus has been previously demonstrated and is currently undergoing phase I monotherapy clinical trials for MM and phase II/III clinical trials for solid tumors. Here we tested the hypothesis that reovirus can successfully purge MM in a murine model that partially recapitulates human MM. RPMI 8226, MM1S, H929 and U266 human myeloma cell lines were exposed to reovirus and oncolysis was assessed. Apheresis product admixed with MM cells was purged with live reovirus (LV) or dead virus (DV) and purging efficacy was monitored via flow cytometry, reverse transcribed-PCR (RT-PCR) and disease relapse in non obese diabetic/severe combined immune deficient (NOD/SCID) mice. Significant LV purging was seen with MM1S, H929 and U266 and the complete ex vivo purging achieved with RPMI 8226 was confirmed by flow cytometry, RT-PCR and absence of disease relapse in vivo. Mice that received LV-purged autografts exhibited 100% survival in comparison to mice that received DV-purged controls. Reovirus's unique ability to kill MM while sparing hematopoietic stem cells places it as an attractive purging agent for MM during ASCT.
[Mh] Termos MeSH primário: Purging da Medula Óssea/métodos
Mieloma Múltiplo/terapia
Terapia Viral Oncolítica
Reoviridae
[Mh] Termos MeSH secundário: Animais
Remoção de Componentes Sanguíneos
Linhagem Celular
Linhagem Celular Tumoral
Citometria de Fluxo
Proteínas de Fluorescência Verde/química
Seres Humanos
Masculino
Camundongos
Camundongos Endogâmicos NOD
Camundongos SCID
Recidiva
Reação em Cadeia da Polimerase Via Transcriptase Reversa
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
147336-22-9 (Green Fluorescent Proteins)
[Em] Mês de entrada:1409
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130827
[St] Status:MEDLINE
[do] DOI:10.1038/bmt.2013.130


  8 / 1097 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24369167
[Au] Autor:Zhang C; Wang XP; Ying ZT; Ping LY; Zheng W; Xie Y; Lin NJ; Liu WP; Deng LJ; Song YQ; Zhu J
[Ad] Endereço:Peking University Cancer Hospital & Institute, Department of Lymphoma, Key Laboratory of Carcinogenesis & Translational Research Ministry of Education, Beijing 100142, China.
[Ti] Título:[Purging with rituximab in vivo combined with autologous peripheral blood stem cell transplantation for aggressive B-cell lymphoma: clinical analysis of 26 cases].
[So] Source:Zhonghua Xue Ye Xue Za Zhi;34(12):1063-5, 2013 Dec.
[Is] ISSN:0253-2727
[Cp] País de publicação:China
[La] Idioma:chi
[Mh] Termos MeSH primário: Anticorpos Monoclonais Murinos/uso terapêutico
Purging da Medula Óssea
Linfoma de Células B/terapia
Transplante de Células-Tronco de Sangue Periférico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Feminino
Seres Humanos
Masculino
Meia-Idade
Estudos Retrospectivos
Rituximab
Transplante Autólogo
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Murine-Derived); 4F4X42SYQ6 (Rituximab)
[Em] Mês de entrada:1502
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:131227
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0253-2727.2013.12.015


  9 / 1097 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24062407
[Au] Autor:Pettengell R; Schmitz N; Dreger P; Goldstone A
[Ad] Endereço:St George's University of London, London, United Kingdom.
[Ti] Título:Reply to C. Fozza.
[So] Source:J Clin Oncol;31(30):3847-8, 2013 Oct 20.
[Is] ISSN:1527-7755
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anticorpos Monoclonais Murinos/uso terapêutico
Antineoplásicos/uso terapêutico
Purging da Medula Óssea/métodos
Linfoma Folicular/terapia
Transplante de Células-Tronco/métodos
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Masculino
[Pt] Tipo de publicação:COMMENT; LETTER
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Murine-Derived); 0 (Antineoplastic Agents)
[Em] Mês de entrada:1312
[Cu] Atualização por classe:131021
[Lr] Data última revisão:
131021
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130925
[St] Status:MEDLINE
[do] DOI:10.1200/JCO.2013.51.8951


  10 / 1097 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24062390
[Au] Autor:Fozza C
[Ad] Endereço:University of Sassari, Sassari, Italy.
[Ti] Título:Rituximab maintenance or retreatment after autologous transplantation for relapsed follicular lymphoma?
[So] Source:J Clin Oncol;31(30):3846-7, 2013 Oct 20.
[Is] ISSN:1527-7755
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anticorpos Monoclonais Murinos/uso terapêutico
Antineoplásicos/uso terapêutico
Purging da Medula Óssea/métodos
Linfoma Folicular/terapia
Transplante de Células-Tronco/métodos
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Masculino
[Pt] Tipo de publicação:COMMENT; LETTER
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Murine-Derived); 0 (Antineoplastic Agents)
[Em] Mês de entrada:1312
[Cu] Atualização por classe:131021
[Lr] Data última revisão:
131021
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130925
[St] Status:MEDLINE
[do] DOI:10.1200/JCO.2013.51.5486



página 1 de 110 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde